Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat

Evolus (EOLS) Prices 5.217M Share Common Offering at $13/Sh

November 7, 2019 5:45 AM EST

Evolus, Inc. (NASDAQ: EOLS) (Evolus) announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions. Evolus is expected to receive net proceeds of approximately $63.5 million, after deducting underwriting... More

Evolus (EOLS) PT Raised to $14 at Barclays

November 5, 2019 4:46 AM EST

Barclays analyst Balaji Prasad raised the price target on Evolus (NASDAQ: EOLS) to $14.00 (from $13.00) while maintaining a Underweight rating.... More

Pre-Open Movers 11/04: (WMGI) (EOLS) (TWOU) Higher; (AVEO) (CHFS) (UAA) Lower (more...)

November 4, 2019 9:28 AM EST

Today's Pre-Open Movers

AVEO Oncology (NASDAQ: AVEO) 37.4% LOWER; provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the Companys proposal to proceed with a New Drug Application (NDA) for tivozanib... In the FDAs preliminary feedback, based on its assessment of the totality of evidence presented to date, the FDA recommended that the Company not submit an NDA at this time. The FDA stated... More

Evolus (EOLS) Tops Q3 EPS by 15c, Revenues Beat

November 4, 2019 7:09 AM EST

Evolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $4.05 million.

This was an exceptional quarter for the company on many fronts, in the U.S. and internationally,... More

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

November 1, 2019 7:52 AM EDT

By Tamara Mathias and Carl O'Donnell

(Reuters) - AbbVie Inc (NYSE: ABBV) on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc (NYSE: AGN).

Shares of the Illinois-based drugmaker rose more than 3% to $82.10.

AbbVie is counting on the Allergan acquisition, expected to close early next year, to help lessen its dependence on Humira, the world's top selling medicine, and diversify its product portfolio.

... More